Physician profile
Mark T White
NPI 1114997640
$1,807.58
in general payments reported to CMS, 2019-2025
23 companies · $22.47 in 2025
The $22.47 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.51 · 2020: $353 · 2021: $289 · 2022: $565 · 2023: $547 · 2025: $22.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $569.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $409.36 | 2021-2023 | Ubrelvy, Vraylar, Qulipta |
| Amarin Pharma, INC. | $228.02 | 2020-2021 | |
| Antares Pharma, INC. | $141.53 | 2019-2023 | Nocdurna, Xyosted, Tlando |
| Sanofi-Aventis U.S. LLC | $129.67 | 2020-2023 | |
| Amgen INC. | $117.66 | 2020-2022 | |
| Glaxosmithkline, LLC. | $106.93 | 2020-2023 | Shingrix, Arexvy |
| Abbott Laboratories | $83.67 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Lilly USA, LLC | $81.90 | 2022-2023 | Jardiance, Mounjaro |
| Pfizer INC. | $76.86 | 2021-2023 | |
| Novo Nordisk INC | $67.80 | 2020-2023 | Ozempic |
| Novartis Pharmaceuticals Corporation | $45.27 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.36 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $38.04 | 2020-2022 | |
| Daiichi Sankyo INC. | $36.60 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $35.82 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $32.50 | 2022 | |
| Merck Sharp & Dohme LLC | $28.61 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $21.85 | 2023 | Breztri |
| Esperion Therapeutics, INC. | $19.65 | 2020 | |
| Ironwood Pharmaceuticals, INC | $19.02 | 2023 | Linzess |
| Idorsia Pharmaceuticals US INC | $17.59 | 2023 | Quviviq |
| Acadia Pharmaceuticals INC | $15.43 | 2021 | |
| Clarus Therapeutics INC. | $11.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.